Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe

Emanuel Raschi, Elisabetta Poluzzi, Brian Godman, Ariola Koci, Ugo Moretti, Marija Kalaba, Marion Bennie, Corrado Barbui, Bjorn Wettermark, Miriam Sturkenboom, Fabrizio De Ponti

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (b) we collected drug utilization data from 12 European Countries to assess the population exposure over the 2005-2010 period.
FAERS data (2004-2010) were analyzed based on the following criteria: (1) ≥ 4 cases of TdP/QT abnormalities; (2) Significant Reporting Odds Ratio, ROR [Lower Limit of the 95% confidence interval>1], for TdP/QT abnormalities, adjusted and stratified (Arizona CERT drugs as effect modifiers); (3) ≥ 4 cases of ventricular arrhythmia/sudden cardiac death (VA/SCD); (4) Significant ROR for VA/SCD; (5) Significant ROR, combined by aggregating TdP/QT abnormalities with VA and SCD. Torsadogenic signals were characterized in terms of signal strength: from Group A (very strong torsadogenic signal: all criteria fulfilled) to group E (unclear/uncertain signal: only 2/5 criteria). Consumption data were retrieved from 12 European Countries and expressed as defined daily doses per 1,000 inhabitants per day (DID).
Thirty-five antipsychotics met at least one criterium: 9 agents were classified in Group A (amisulpride, chlorpromazine, clozapine, cyamemazine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). In 2010, the overall exposure to antipsychotics varied from 5.94 DID (Estonia) to 13.99 (France, 2009). Considerable increment of Group A agents was found in several Countries (+3.47 in France): the exposure to olanzapine increased across all Countries (+1.84 in France) and peaked 2.96 in Norway; cyamemazine was typically used only in France (2.81 in 2009). Among Group B drugs, levomepromazine peaked 3.78 (Serbia); fluphenazine 1.61 (Slovenia).
This parallel approach through spontaneous reporting and drug utilization analyses highlighted drug- and Country-specific scenarios requiring potential regulatory consideration: levomepromazine (Serbia), fluphenazine (Slovenia), olanzapine (across Europe), cyamemazine (France). This synergy should be encouraged to support future pharmacovigilance activities.

LanguageEnglish
Article numbere81208
JournalPLOS One
Volume8
Issue number11
DOIs
Publication statusPublished - 20 Nov 2013

Fingerprint

Drug Utilization
olanzapine
Torsades de Pointes
Antipsychotic Agents
France
drugs
Methotrimeprazine
Fluphenazine
Slovenia
Serbia
Pharmaceutical Preparations
arrhythmia
Sudden Cardiac Death
Cardiac Arrhythmias
haloperidol
Estonia
death
chlorpromazine
Pharmacovigilance
Risperidone

Keywords

  • torsadogenic risk
  • antipsychotics
  • adverse event reports
  • drug utilization data
  • europe
  • torsade de pointes

Cite this

Raschi, Emanuel ; Poluzzi, Elisabetta ; Godman, Brian ; Koci, Ariola ; Moretti, Ugo ; Kalaba, Marija ; Bennie, Marion ; Barbui, Corrado ; Wettermark, Bjorn ; Sturkenboom, Miriam ; De Ponti, Fabrizio. / Torsadogenic risk of antipsychotics : combining adverse event reports with drug utilization data across Europe. In: PLOS One. 2013 ; Vol. 8, No. 11.
@article{cfa3849711a54a42a90e03a1fffa7e26,
title = "Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe",
abstract = "Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (b) we collected drug utilization data from 12 European Countries to assess the population exposure over the 2005-2010 period. FAERS data (2004-2010) were analyzed based on the following criteria: (1) ≥ 4 cases of TdP/QT abnormalities; (2) Significant Reporting Odds Ratio, ROR [Lower Limit of the 95{\%} confidence interval>1], for TdP/QT abnormalities, adjusted and stratified (Arizona CERT drugs as effect modifiers); (3) ≥ 4 cases of ventricular arrhythmia/sudden cardiac death (VA/SCD); (4) Significant ROR for VA/SCD; (5) Significant ROR, combined by aggregating TdP/QT abnormalities with VA and SCD. Torsadogenic signals were characterized in terms of signal strength: from Group A (very strong torsadogenic signal: all criteria fulfilled) to group E (unclear/uncertain signal: only 2/5 criteria). Consumption data were retrieved from 12 European Countries and expressed as defined daily doses per 1,000 inhabitants per day (DID). Thirty-five antipsychotics met at least one criterium: 9 agents were classified in Group A (amisulpride, chlorpromazine, clozapine, cyamemazine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). In 2010, the overall exposure to antipsychotics varied from 5.94 DID (Estonia) to 13.99 (France, 2009). Considerable increment of Group A agents was found in several Countries (+3.47 in France): the exposure to olanzapine increased across all Countries (+1.84 in France) and peaked 2.96 in Norway; cyamemazine was typically used only in France (2.81 in 2009). Among Group B drugs, levomepromazine peaked 3.78 (Serbia); fluphenazine 1.61 (Slovenia). This parallel approach through spontaneous reporting and drug utilization analyses highlighted drug- and Country-specific scenarios requiring potential regulatory consideration: levomepromazine (Serbia), fluphenazine (Slovenia), olanzapine (across Europe), cyamemazine (France). This synergy should be encouraged to support future pharmacovigilance activities.",
keywords = "torsadogenic risk, antipsychotics, adverse event reports, drug utilization data , europe, torsade de pointes",
author = "Emanuel Raschi and Elisabetta Poluzzi and Brian Godman and Ariola Koci and Ugo Moretti and Marija Kalaba and Marion Bennie and Corrado Barbui and Bjorn Wettermark and Miriam Sturkenboom and {De Ponti}, Fabrizio",
year = "2013",
month = "11",
day = "20",
doi = "10.1371/journal.pone.0081208",
language = "English",
volume = "8",
journal = "PLOS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Raschi, E, Poluzzi, E, Godman, B, Koci, A, Moretti, U, Kalaba, M, Bennie, M, Barbui, C, Wettermark, B, Sturkenboom, M & De Ponti, F 2013, 'Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe' PLOS One, vol. 8, no. 11, e81208. https://doi.org/10.1371/journal.pone.0081208

Torsadogenic risk of antipsychotics : combining adverse event reports with drug utilization data across Europe. / Raschi, Emanuel; Poluzzi, Elisabetta; Godman, Brian; Koci, Ariola; Moretti, Ugo; Kalaba, Marija; Bennie, Marion; Barbui, Corrado; Wettermark, Bjorn; Sturkenboom, Miriam; De Ponti, Fabrizio.

In: PLOS One, Vol. 8, No. 11, e81208, 20.11.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Torsadogenic risk of antipsychotics

T2 - PLOS One

AU - Raschi, Emanuel

AU - Poluzzi, Elisabetta

AU - Godman, Brian

AU - Koci, Ariola

AU - Moretti, Ugo

AU - Kalaba, Marija

AU - Bennie, Marion

AU - Barbui, Corrado

AU - Wettermark, Bjorn

AU - Sturkenboom, Miriam

AU - De Ponti, Fabrizio

PY - 2013/11/20

Y1 - 2013/11/20

N2 - Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (b) we collected drug utilization data from 12 European Countries to assess the population exposure over the 2005-2010 period. FAERS data (2004-2010) were analyzed based on the following criteria: (1) ≥ 4 cases of TdP/QT abnormalities; (2) Significant Reporting Odds Ratio, ROR [Lower Limit of the 95% confidence interval>1], for TdP/QT abnormalities, adjusted and stratified (Arizona CERT drugs as effect modifiers); (3) ≥ 4 cases of ventricular arrhythmia/sudden cardiac death (VA/SCD); (4) Significant ROR for VA/SCD; (5) Significant ROR, combined by aggregating TdP/QT abnormalities with VA and SCD. Torsadogenic signals were characterized in terms of signal strength: from Group A (very strong torsadogenic signal: all criteria fulfilled) to group E (unclear/uncertain signal: only 2/5 criteria). Consumption data were retrieved from 12 European Countries and expressed as defined daily doses per 1,000 inhabitants per day (DID). Thirty-five antipsychotics met at least one criterium: 9 agents were classified in Group A (amisulpride, chlorpromazine, clozapine, cyamemazine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). In 2010, the overall exposure to antipsychotics varied from 5.94 DID (Estonia) to 13.99 (France, 2009). Considerable increment of Group A agents was found in several Countries (+3.47 in France): the exposure to olanzapine increased across all Countries (+1.84 in France) and peaked 2.96 in Norway; cyamemazine was typically used only in France (2.81 in 2009). Among Group B drugs, levomepromazine peaked 3.78 (Serbia); fluphenazine 1.61 (Slovenia). This parallel approach through spontaneous reporting and drug utilization analyses highlighted drug- and Country-specific scenarios requiring potential regulatory consideration: levomepromazine (Serbia), fluphenazine (Slovenia), olanzapine (across Europe), cyamemazine (France). This synergy should be encouraged to support future pharmacovigilance activities.

AB - Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (b) we collected drug utilization data from 12 European Countries to assess the population exposure over the 2005-2010 period. FAERS data (2004-2010) were analyzed based on the following criteria: (1) ≥ 4 cases of TdP/QT abnormalities; (2) Significant Reporting Odds Ratio, ROR [Lower Limit of the 95% confidence interval>1], for TdP/QT abnormalities, adjusted and stratified (Arizona CERT drugs as effect modifiers); (3) ≥ 4 cases of ventricular arrhythmia/sudden cardiac death (VA/SCD); (4) Significant ROR for VA/SCD; (5) Significant ROR, combined by aggregating TdP/QT abnormalities with VA and SCD. Torsadogenic signals were characterized in terms of signal strength: from Group A (very strong torsadogenic signal: all criteria fulfilled) to group E (unclear/uncertain signal: only 2/5 criteria). Consumption data were retrieved from 12 European Countries and expressed as defined daily doses per 1,000 inhabitants per day (DID). Thirty-five antipsychotics met at least one criterium: 9 agents were classified in Group A (amisulpride, chlorpromazine, clozapine, cyamemazine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). In 2010, the overall exposure to antipsychotics varied from 5.94 DID (Estonia) to 13.99 (France, 2009). Considerable increment of Group A agents was found in several Countries (+3.47 in France): the exposure to olanzapine increased across all Countries (+1.84 in France) and peaked 2.96 in Norway; cyamemazine was typically used only in France (2.81 in 2009). Among Group B drugs, levomepromazine peaked 3.78 (Serbia); fluphenazine 1.61 (Slovenia). This parallel approach through spontaneous reporting and drug utilization analyses highlighted drug- and Country-specific scenarios requiring potential regulatory consideration: levomepromazine (Serbia), fluphenazine (Slovenia), olanzapine (across Europe), cyamemazine (France). This synergy should be encouraged to support future pharmacovigilance activities.

KW - torsadogenic risk

KW - antipsychotics

KW - adverse event reports

KW - drug utilization data

KW - europe

KW - torsade de pointes

U2 - 10.1371/journal.pone.0081208

DO - 10.1371/journal.pone.0081208

M3 - Article

VL - 8

JO - PLOS One

JF - PLOS One

SN - 1932-6203

IS - 11

M1 - e81208

ER -